Hypofractionated Postmastectomy Radiotherapy Holds Local Control in High-Risk Breast Cancer
When internal mammary node irradiation is part of postmastectomy treatment, the long-standing concern has been whether shorter courses can preserve tumor control without adding cardiac or pulmonary risk. The HypoMast-IMNI phase III trial now gives that question a direct answer for a large cohort of patients with high-risk, operable breast cancer: hypofractionated radiotherapy delivered over 16 fractions was noninferior to conventional treatment for locoregional control, while also reducing acute skin toxicity.
Between September 2018 and July 2022, 1,494 patients were randomly assigned to either 42.56 Gy in 16 fractions or 50 Gy in 25 fractions. Both regimens treated the chest wall and regional lymph nodes, including the internal mammary nodes. The study population represented the kind of postmastectomy setting that radiotherapy teams often consider the most technically demanding, because coverage of the internal mammary chain can raise concern about exposure to nearby heart and lung structures. Here, those concerns were tested under randomized phase III conditions rather than inferred from retrospective experience.
Noninferior Locoregional Control With a Shorter Course
The primary endpoint was locoregional recurrence, and the trial met its noninferiority criterion. After a median follow-up of 58.1 months in the modified intention-to-treat population of 1,429 patients, the 5-year cumulative incidence of locoregional recurrence was 1.7% with hypofractionation and 2.2% with conventional fractionation. The hazard ratio was 0.69 with a 95% confidence interval of 0.32 to 1.51, and the noninferiority test reached significance with P = .017.
The numbers are small because both arms performed well. In practical terms, that matters as much as the hazard ratio itself. A low event rate means the question is not whether one regimen rescued a poor outcome, but whether the shorter course can sustain already strong control while easing treatment burden for patients and clinics. The answer was yes.
No Signal of Inferior Distant or Survival Outcomes
Secondary efficacy outcomes remained aligned across arms. No significant differences emerged in distant metastasis-free survival, breast cancer recurrence-free survival, disease-free survival, or overall survival at 5 years. For a locoregional treatment strategy, that pattern is clinically reassuring because it argues against any hidden tradeoff in the form of more distant relapse or survival compromise after shortening the schedule.
The biology behind the result is plausible. Postmastectomy radiotherapy aims to sterilize microscopic residual disease in the chest wall and regional nodal basins after surgery, and fractionation changes dose delivery more than the fundamental antitumor target. In this trial, the shorter regimen appears to have maintained sufficient biologic effect across the chest wall and internal mammary chain while preserving the same regional treatment intent. The data support a radiobiologic premise that breast cancer PMRT can sometimes be compressed without sacrificing efficacy, even when the internal mammary nodes are included.
Acute Skin Toxicity Fell Sharply With Hypofractionation
The clearest safety difference emerged early. Grade 3 acute skin toxicity occurred in 1.7% of patients treated with hypofractionation versus 12.2% with conventional fractionation, a highly significant difference (P < .001). That gap is clinically meaningful at the bedside. Skin reactions are among the most immediate reasons radiotherapy becomes difficult for patients to tolerate, and severe dermatitis can disrupt daily function, increase supportive care needs, and complicate treatment continuity.
A shorter course does not merely save time on the calendar. It can reduce the cumulative burden of repeated visits and may lessen the peak acute inflammatory injury seen in the irradiated skin envelope. In a postmastectomy setting, where chest wall treatment often spans a broad surface area and may extend toward the supraclavicular and internal mammary fields, that reduction in dermatitis can shape the entire treatment experience.
Cardiopulmonary Safety Remained Reassuring Despite IMN Coverage
Coverage of the internal mammary nodes is where many clinicians remain most cautious, because those fields can bring the heart and lungs into the beam path. In this trial, the incidence of grade 2 or higher radiation pneumonitis and pulmonary fibrosis was low and comparable between arms. No ischemic cardiac events were recorded.
For a study built around IMN irradiation, that absence of cardiac events is particularly important, even if follow-up is still limited relative to the decades over which radiation-induced heart disease can appear. The near-term message is that a 16-fraction regimen did not create an obvious cardiopulmonary penalty compared with the conventional schedule. Modern planning and delivery likely contributed to that safety profile, but the clinical takeaway is simpler: internal mammary coverage did not force a tradeoff between shorter treatment and immediate organ toxicity in this randomized population.
What This Means for High-Risk Operable Breast Cancer
The enrolled population included patients with pT1-4N2-3, pT3-4N1, or pT1-2N1 disease with additional high-risk factors, so this was not a low-risk mastectomy cohort. These were patients in whom postmastectomy radiotherapy is already considered an important part of risk reduction, and the need to treat regional nodes, including the internal mammary chain, makes the logistics more complex. In that context, a noninferior shorter regimen has direct implications for treatment access, scheduling, and patient convenience.
The randomized evidence now places hypofractionated PMRT with IMNI on firmer ground. It delivers the same locoregional control benchmark expected from conventional fractionation, with less severe acute skin toxicity and no apparent early cardiopulmonary disadvantage. For radiation oncologists, the decision may shift from whether shorter treatment is acceptable to how broadly it can be adopted in patients whose anatomy and nodal risk require internal mammary coverage.
Longer follow-up will still matter for late toxicity, especially cardiac outcomes, because radiation-associated cardiovascular injury can emerge years after treatment. The trial’s current follow-up is enough to define early efficacy and acute safety, but not enough to fully close the book on late vascular and myocardial effects. The remaining clinical question is not whether the shorter regimen works now, but whether its favorable safety profile persists as the cohort matures over time.